Literature DB >> 25730813

Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus.

Sidra Azeem1, Muhammad Ashraf1, Muhammad Adil Rasheed1, Aftab Ahmad Anjum2, Rabia Hameed1.   

Abstract

Cytotoxic and antiviral potential of ivermectin and ribavirin was evaluated. Cytotoxicity was checked on chick primary fibroblast cell line through MTT assay. Antiviral potential was determined against Newcastle disease virus on 9-day old chicken embryos. Six different concentrations (200, 100, 50, 25, 12.5 and 6.25μg/ml) of both the drugs were evaluated. The 100μg/ml concentration of ivermectin and higher were cytotoxic. The 25μg/ml concentration of ribavirin and higher were cytotoxic. Comparison of ivermectin and ribavirin showed that ivermectin was safe at 50μg/ml and lower concentrations. Ribavirin was protective for cell at 12.5μg/ml and 6.25μg/ml only. Comparison of antiviral activity indicated that ivermectin has strong antiviral potential at 100μg/ml and higher but same concentrations were cytotoxic. Ribavirin showed strong antiviral potential at all concentrations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25730813

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  11 in total

Review 1.  A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.

Authors:  Robert T Kinobe; Leigh Owens
Journal:  Fundam Clin Pharmacol       Date:  2021-01-28       Impact factor: 2.748

2.  The Politicization of Ivermectin Tweets During the COVID-19 Pandemic.

Authors:  Marlon I Diaz; John J Hanna; Amy E Hughes; Christoph U Lehmann; Richard J Medford
Journal:  Open Forum Infect Dis       Date:  2022-06-06       Impact factor: 4.423

3.  Structural evaluation of the peritubular sheath of rat's testes after administration of ribavirin: A possible impact on the testicular function.

Authors:  Shaima M Almasry; Zeinab A Hassan; Wael M Elsaed; Yasser M Elbastawisy
Journal:  Int J Immunopathol Pharmacol       Date:  2017-08-11       Impact factor: 3.219

4.  Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.

Authors:  Khan Sharun; Kuldeep Dhama; Shailesh Kumar Patel; Mamta Pathak; Ruchi Tiwari; Bhoj Raj Singh; Ranjit Sah; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales; Hakan Leblebicioglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-05-30       Impact factor: 3.944

Review 5.  Known drugs and small molecules in the battle for COVID-19 treatment.

Authors:  Alexios A Panoutsopoulos
Journal:  Genes Dis       Date:  2020-06-20

6.  Regression of bovine cutaneous papillomas via ivermectin-induced immunostimulant and oxidative stress.

Authors:  AbdulRahman A Saied
Journal:  J Adv Vet Anim Res       Date:  2021-07-20

7.  Evaluation of ivermectin antiviral activity against avian infectious bronchitis virus using a chicken embryo model.

Authors:  Donald L Reynolds; E Barry Simpson
Journal:  Int J Vet Sci Med       Date:  2022-03-25

8.  Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.

Authors:  Arif Jamal Siddiqui; Sadaf Jahan; Syed Amir Ashraf; Mousa Alreshidi; Mohammad Saquib Ashraf; Mitesh Patel; Mejdi Snoussi; Ritu Singh; Mohd Adnan
Journal:  J Biomol Struct Dyn       Date:  2020-08-05

9.  Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.

Authors:  Zaki F Aref; Shamardan Ezz Eldin S Bazeed; Mohammed H Hassan; Abeer S Hassan; Alaa Rashad; Rehab G Hassan; Aida A Abdelmaksoud
Journal:  Int J Nanomedicine       Date:  2021-06-15

10.  Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.

Authors:  Fatemeh Heidary; Reza Gharebaghi
Journal:  J Antibiot (Tokyo)       Date:  2020-06-12       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.